Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Apimeds Pharmaceuticals US, Inc. (APUS) Stock-Based Compensation data is not available for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-1.39M |
|
-- |
|
-- |
|
$1.28M |
|
$-1.28M |
|
$-0.11M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.39M |
|
$-1.28M |
|
$-1.28M |
|
7.90M |
|
7.90M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$0.01M |
|
-- |
|
-- |
|
$0.01M |
|
$1.02M |
|
$0.35M |
|
$0.35M |
|
$1.37M |
|
$-1.36M |
|
$-1.36M |
|
$-1.36M |
|
7.90M |
|
| Cash Flow Statement Financials | |
$-0.73M |
|
-- |
|
$0.33M |
|
$0.41M |
|
$0.00M |
|
$-0.41M |
|
|
Stock-Based Compensation |
-- |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.01 |
|
-- |
|
-- |
|
-0.34 |
|
-0.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
102.35% |
|
102.35% |
|
-10645.55% |
|
137.45% |
|
$-0.17 |
|
$-0.09 |
|
$-0.09 |
|